Singleron Biotechnologies is named as one of the Top 100 Future Healthcare Firms (VC100), and one of the Top 20 Molecular Diagnostics Firms in China by the industry research branch of VCBeat, a professional services organization in the Chinese healthcare industry.
Starting in 2015, VC100 is an annual list of non-public healthcare companies that VCBeat believes will shape the future of the Chinese healthcare industry. VCBeat selects the companies based on their core technologies, commercialization progress, and other competitive advantages.
Founded in 2018, Singleron has dedicated to applying groundbreaking single cell analysis technologies to clinical diagnosis, drug development and health management. Singleron is currently working with multiple prominent hospitals in China to translate single cell technologies to clinics.